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A B S T R A C T
Some soil bacteria are able to metabolize styrene via initial side-chain oxygenation. This catabolic route is
of potential biotechnological relevance due to the occurrence of phenylacetic acid as a central metabolite.
Thestyrene-degrading strains Rhodococcus opacus 1CP, Pseudomonas ﬂuorescens ST, and the novel isolates
Sphingopyxis sp. Kp5.2 and Gordonia sp. CWB2 were investigated with respect to their applicability to
co-metabolically produce substituted phenylacetic acids. Isolates were found to differ signiﬁcantly in
substrate tolerance and biotransformation yields. Especially, P. ﬂuorescens ST was identiﬁed as a promising
candidate for the production of several phenylacetic acids. The biotransformation of 4-chlorostyrene
with cells of strain ST was shown to be stable over a period of more than 200 days and yielded
about 38 mmolproduct gcelldryweight1 after nearly 350 days. Moreover, 4-chloro-a-methylstyrene was
predominantly converted to the (S)-enantiomer of the acid with 40% enantiomeric excess.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Phenylacetic acids represent an important class of compounds
for several industries. They occur as natural ingredients in plants
and fruits and are used as ﬂavors and fragrances in cosmetics or
food [14]. Additionally, these compounds have a high relevance for
the pharmaceutical sector as precursors or drugs [29,51]. For
example, a-methylated phenylacetic acids are currently applied as
starting materials for the production of virostatic agents [49] or for
receptor agonists and antagonists, e.g. for the histamine H2
receptor [15,19]. Phenylacetic acids also serve as precursors for
analgesics like diclofenac [40,41,44] or show already an analgesic
effect like 4-isobutyl-a-methylphenylacetic acid which is also
known as ibuprofen [8,12]. Furthermore, antibiotics on the basis of
penicillin can be obtained from 4-hydroxyphenylacetic acid or
non-substituted phenylacetic acid [9,11].
Because of the versatile applications of phenylacetic acids,
different chemical strategies for their synthesis have been devel-
oped. The hydrolysis of phenylacetonitrile and its analogs in the
presence of mineral acids at temperatures of up to 250 C is one
important way to produce phenylacetic acids [24]. Another
important alternative is the carbonylation of benzyl chlorides in
the presence of ruthenium(III) EDTA complexes [45], nickel catalysts* Correspondence author. Tel.: +49 3731 394015; fax: +49 3731 393012
E-mail address: michel.oelschlaegel@ioez.tu-freiberg.de (M. Oelschlägel).
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compounds mentioned use a-hydroxynitriles [2], styrene and
derivatives [8], or mandelic acid [29]. The a-methylated phenyl-
acetic acids like ibuprofen are commonlyobtained viacorresponding
phenylacetophenones from substituted- or non-substituted
benzenes after initial Friedel–Crafts acylation [3,12,28,43].
As an alternative to chemical syntheses biotechnological
strategies have been investigated to obtain aromatic acids. Gilligan
et al. [16] transformed racemic 2-phenylpropionitrile via an amide
to (S)-2-phenylpropionic acid applying a nitrile hydratase
(EC 4.2.1.84) and a stereoselective amidase (EC 3.5.1.4) from
Rhodococcus equi TG328. A remarkable enantiomeric excess (ee) of
about 99% was achieved. The amidase of Agrobacterium tumefaciens
d3 is also able to convert racemic 2-phenylpropionamide into the
corresponding acid with an ee of 95% [48]. Sosedov et al. [42] have
reported the direct hydrolysis of arylacetonitriles to phenylacetic
acids by a recombinant arylacetonitrilase (EC 3.5.5.1) from
Pseudomonas ﬂuorescens EBC191.
Another biotechnological route to phenylacetic acids seems
feasible applying styrenes. These styrenes are partly available in
large amounts from the polymer industry [23] and can be
converted by soil bacteria harboring enzymes of the styrene-
catabolic pathway of side-chain oxygenation [32,36]. During side-
chain oxygenation, the substrate styrene is initially oxidized into
styrene oxide by styrene monooxygenase (SMO, EC 1.14.14.11,
encoded by styA/styB) and subsequently transformed into phenyl-
acetaldehyde by styrene oxide isomerase (SOI, EC 5.3.99.7, encodedder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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aldehyde is oxidized to phenylacetic acid by phenylacetaldehyde
dehydrogenase (PAD, EC 1.2.1.39, styD). The formed acid represents
a substrate of the phenylacetyl-CoA ligase, which is the initial
enzyme of the lower degradation pathway [7,37,38,46]. A
modiﬁcation of this pathway by deletion or substitution of
enzymes is possible as mentioned by Hartmans et al. [20] or Toda
and Itoh [47] . Previous studies have elucidated enzymes involved
in the side-chain oxygenation of styrene in, for example,
representatives of the genera Corynebacterium,Rhodococcus,
Pseudomonas, Sphingopyxis, or Xanthobacter [5,20,22,33–35,47].
This study investigates the applicability of the styrene-
degrading strains Rhodococcus opacus 1CP, P. ﬂuorescens ST,
Sphingopyxis sp. Kp5.2, and Gordonia sp. CWB2 as whole-cell
biocatalysts for the co-metabolic production of substituted
phenylacetic acids from corresponding styrenes.
2. Material and methods
2.1. Chemicals
Standard chemicals, substituted and non-substituted styrenes,
styrene oxides, phenylacetaldehydes, and phenylacetic acids were
purchased from Sigma–Aldrich (Steinheim, Germany), Merck KGaK
(Darmstadt, Germany), AppliChem GmbH (Darmstadt, Germany),
VWR International GmbH (Darmstadt, Germany), Riedel-de Haën
(Seelze, Germany), Fisher Scientiﬁc (Loughborough, UK), Bio-Rad
Laboratories GmbH (München, Germany), or Carl Roth (Karlsruhe,
Germany) in highest purity available. The enantiomers of 4-chloro-
a-methylphenylacetic acid were produced by the workgroup of
Prof. Dr. Isamu Shiina (Tokyo University of Science) as described
earlier [39].
4-Isobutyl-a-methylstyrene was obtained by Wittig-reaction
of 4-isobutylacetophenone and in-situ-generated methylenetri-
phenylphosphorane according a protocol of [21]. The reaction
product was puriﬁed by vacuum distillation and ﬂash chroma-
tography (silica gel, hexane) to yield the styrene as a colorless
liquid. The retarded liquid contained 99% 4-isobutyl-a-methyl-
styrene (1.77 g, 10.2 mmol, 25.5% total yield). Purity was deter-
mined by silica gel chromatography and GC analysis while correct
product formation was controlled via H NMR spectroscopy.
2.2. Bacterial strains and culture conditions
R. opacus 1CP (VKM Ac-2638 [18]), P. ﬂuorescens ST (DSM 6290
[4,5]) Sphingopyxis sp. Kp5.2 (DSM 28731 [35]), and Gordonia sp.
CWB2 (DSM 46758 [35]) were cultivated on mineral mediumFig.1. Biotransformation of styrene and substituted analogs to phenylacetic acid(s).
Styrene (R1, R2 = H) is transformed to phenylacetic acid through enzymes of side-
chain oxygenation by the following steps: (a) initial epoxidation to styrene oxide by
styrene monooxygenase (SMO), (b) isomerization to phenylacetaldehyde by styrene
oxide isomerase (SOI), (c) oxidation by phenylacetaldehyde dehydrogenase (PAD)
(reviewed by [32,36]). A star indicates the formation of a stereocenter in case of
R1 = CH3. The suitability of the catabolic route was tested for the formation of 3-
chloro-, 4-chloro-, 4-ﬂuoro-, a-methyl-, 4-chloro-a-methyl-, and 4-isobutyl-
a-methylphenylacetic acid.plates [10] in the presence of 20 g l1 glucose or in presence of
gaseous styrene [34,35] for preservation.
Fed-batch cultivation was initially performed in 500-ml bafﬂed
ﬂasks containing 50 ml mineral medium with 0.05% (w/v) yeast
extract at 30 C under constant shaking (120 rpm). In total
0.5–0.75 mmol glucose were added to the precultures as
0.25-mmol aliquots every 2–5 days. Cell growth was determined
by the optical density at 600 nm (OD600) and the cell dry weight.
The precultures were used to inoculate 1-l bafﬂed ﬂasks
containing 200 ml mineral medium with 0.05% (w/v) yeast extract.
Cultures were incubated at 30 C and 120 rpm. In total 3–4 mmol
glucose were added as 1-mmol aliquots during the ﬁrst 3–4 days.
In order to induce enzymes relevant for biotransformation, in total
about 80 mmol styrene were added in 18–26-mmol portions
through an evaporation adapter for further 5.5–6.5 days. The
biomass obtained was applied immediately for biotransformation
experiments. For this, biomass from two cultures of each strain was
pooled and 200–400 ml of cells were harvested by centrifugation
(5000  g, 30 min, 4 C). The cell pellet was washed twice with
50 ml of 25 mM phosphate buffer (pH 7.0) and centrifuged. The
pellet obtained was suspended in 240–260 ml of fresh 25 mM
phosphate buffer (pH 7.0) and the resulting cell suspension was
used to investigate the substrate tolerance.
For long-time transformation of suitable substrates and strains,
1-l bafﬂed ﬂasks with 200 ml mineral medium containing
0.05–0.1% (w/v) yeast extract were inoculated with biomass from
precultures, which was cultivated as described above, or directly
by cells grown on solid medium or from cryo-cultures. Cultures
were incubated at 30 C and 120 rpm. In total 3.0–4.0 mmol glucose
were added as 1.0-mmol aliquots during 10–11 days. Biomass
obtained was, if appropriate, harvested as described above, pellet
washed with sterile water, and cells subsequently suspended in
200 ml of fresh mineral medium without yeast extract. Cultures
were initially incubated over 3–6 days in 1-l bafﬂed ﬂasks in
presence of styrene (in total about 26–70 mmol, 18–26-mmol
aliquots added through an evaporation adapter) for cell adaptation.
Cells obtained were applied to investigate a fed-batch biotransfor-
mation in order to produce selected phenylacetic acids.
2.3. Investigation of substrate tolerance
20 ml of resuspended cells of each strain were distributed to
500-ml bafﬂed ﬂasks. 25 mmol of one of the following substrates
were subsequently provided by means of an evaporation adapter:
styrene,3-chlorostyrene, 4-chlorostyrene, 4-ﬂuorostyrene,a-meth-
ylstyrene, 4-chloro-a-methylstyrene, 4-isobutyl-a-methylstyrene.
For the latter compound, also the direct addition to the culture
medium was investigated because of its signiﬁcantly reduced
volatility compared to the other styrenes mentioned. Batches were
cultivated at 30 C and 120 rpm for 12 h. To determine product
formation, samples of 750ml were taken from the batches,
centrifuged at 16.000  g for 4 min, and supernatant analyzed by
reversed-phase HPLC. To consider poor solubility of some products,
especially of 4-chloro-a-methylphenylacetic acid and 4-isobutyl-
a-methylphenylacetic acid in the culture medium, samples of
200 ml were diluted with 800 ml methanol. Diluted samples
were mixed, centrifuged at 16.000  g for 30 s, and supernatants
analyzed by reversed-phase HPLC, too. The product yields
determined after 12 h were normalized by the cell dry weight
applied (mmolproduct gcelldryweight1).
2.4. Fed-batch biotransformation for the production of selected
phenylacetic acids
200 ml of a styrene-induced cell suspension of P. ﬂuorescens ST
were incubated with in total 3630 mmol 4-chlorostyrene which
Fig. 2. (a) Chromatographic and (b) spectral identiﬁcation of the metabolite
phenylacetic acid during styrene degradation of strains Kp5.2, CWB2, and 1CP.
Cell suspensions of Sphingopyxis sp. Kp5.2, Gordonia sp. CWB2, and Rhodococcus
opacus 1CP were cultured and induced as described in the Section 2 and
subsequently incubated for 12 h in the presence of 25 mmol gaseous styrene in 500-
ml ﬂasks. Culture supernatant was subjected to HPLC under conditions described in
Section 2.
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during 348 days. During the complete cultivation in total about
1750 mmol styrene were additionally supplied in portions of
19–20 mmol via the evaporation adapter to ensure cell adaptation.
A further culture of strain ST containing 200 ml of biomass was
incubated in presence of in total 374 mmol 4-chloro-a-methyl-
styrene (added in 20–41-mmol aliquots via the evaporation
adapter) for 25 days. Beside the halogenated substrate,
also styrene was added in a total amount of about 196 mmol by
19–20-mmol portions via gas phase.
The transformation of in total 650 mmol 4-isobutyl-a-methyl-
styrene was investigated with 200 ml of a culture containing
Gordonia sp. CWB2 over 28 days. The substrate was added in
50–100-mmol aliquots directly to the medium. Styrene was
additionally fed to the culture through an evaporation adapter
(in total about 314 mmol, 26-mmol aliquots).
Samples of 200 ml or 750 ml were frequently taken from the
batches to determine product formation by both methods described
above. Afterwards, samples were analyzed by reversed-phase HPLC.
In all cases, viability of the cells and purity of the cultures was
regularly proven by plating out cell suspension on solid LB medium
or mineral medium containing 20 g l1 glucose.
2.5. Product quantiﬁcation and determination of stereoselectivity
Reversed-phase HPLC was performed on a Dionex instrument
(P680 pump, UVD340S DAD detector, Gina 50 autosampler) using a
vertex column (125 mm length  4 mm i. d.) packed with
Eurospher C18 (5 mm particle size, 100 Å pore size; Knauer, Berlin,
Germany) as described previously [34,35]. The mobile phase,
which contained 50% or 65% (v/v) methanol and 0.1% (w/v)
phosphoric acid, was used in an isocratic mode at a ﬂow rate of
0.7 ml min1. The following net retention volumes were obtained:
phenylacetic acid, 2.8 ml (50% methanol); 3-chlorophenylacetic
acid, 7.1 ml (50%); 4-chlorophenylacetic acid, 7.2 ml (50%);
4-ﬂuorophenylacetic acid, 3.4 ml (50%); a-methylphenylacetic
acid, 5.4 ml (50%); 4-chloro-a-methylphenylacetic acid, 13.7 ml
(50%); 4-isobutyl-a-methylphenylacetic acid, 12.0 ml (65%). Peaks
obtained were compared to authentic standards in respect of
retention volume and UV-spectrum (200–300 nm).
For the chiral product of the 4-chloro-a-methylstyrene
transformation, enantiomeric excess (ee) was determined with a
column (200 mm  4 mm) packed with Nucleodex a-PM (perme-
thylated a-cyclodextrine) on Nucleosil silica (5 mm particle size,
100 Å pore size; Macherey-Nagel, Düren, Germany). 40% methanol
with 0.06% (w/v) triethylammonium acetate (pH 4.1) served as
mobile phase in an isocratic mode and at a ﬂow rate of
0.7 ml min1. Following net retention volumes were observed:
(R)-4-chloro-a-methylphenylacetic acid, 31.6 ml; (S)-4-chloro-
a-methylphenylacetic acid, 33.3 ml.
3. Results and discussion
3.1. Detection of phenylacetic acid as an indicator for styrene
catabolism via side-chain oxygenation
The ability of bacteria to convert styrene into phenylacetic acid
could be an attractive basis for the conversion of substituted
styrenes (Fig. 1), provided that the initial epoxidizing, isomerizing,
and dehydrogenating enzyme activities are sufﬁciently unspeciﬁc.
A restricted substrate spectrum of the following phenylacetate-
converting enzyme then may lead to the accumulation of
structural analogs as dead-end products. Such differences in
substrate tolerance between the peripheral and central pathways
of (chloro- and methyl-) aromatic degradation are well known and
responsible for a number of co-metabolic transformations [25–27].In order to investigate the suitability of the concept mentioned
above, four strains were selected in that respect. The proteobac-
teria P. ﬂuorescens ST and Sphingopyxis sp. Kp5.2 as well as the
actinobacteria R. opacus 1CP and Gordonia sp. CWB2 are known to
utilize styrene as the sole source of energy and carbon [5,7,35].
Although styrene-catabolic genes for side-chain oxygenation have
been identiﬁed in strain ST [5,7], strain Kp5.2 [35], and strain 1CP
[35], their functional relevance for the degradation of styrene has
been demonstrated only for the pseudomonad so far. Despite the
proof of SOI activity in the case of strain 1CP and Kp5.2, it was not
directly shown for the latter two strains if styrene is degraded by
the pathway of side-chain oxygenation yielding phenylacetic
acid as central intermediate. The styrene degradation pathway of
strain CWB2 is even more speculative, since the genetic
background has not yet been investigated. An alternative route
could lead to 3-vinylcatechol which has been reported to be
subject of a meta-cleavage pathway [50].
In order to establish the catabolic pathway of the above
mentioned new isolates, styrene-grown biomass of each strain was
incubated in the presence of this hydrocarbon and the culture
medium was analysed for the occurrence of intermediates. Based
on retention behavior and spectral data, phenylacetic acid could be
detected in concentrations of 3.5–42.5 mM in cultures of strain 1CP,
CWB2, and Kp5.2 after 12 h (Fig. 2). Surprisingly, no phenylacetic
acid accumulated during growth of strain ST. But strain ST is known
to produce this compound as an intermediate [4]. These results
strongly conﬁrm former studies [34,35] and indicate that these
strains mentioned degrade styrene via the route of site-chain
oxygenation.
The considerable differences in concentration level likely result
from strain-speciﬁc kinetics of phenylacetic acid formation and
consumption. As shown later, these levels do not necessarily allow
a conclusion to the suitability of an isolate to accumulate
substituted analogs of phenylacetic acid.
Fig. 4. 3-Chlorostyrene conversion by strains ST, Kp5.2, 1CP, and CWB2.
Pseudomonas ﬂuorescens ST (0.61 mgcdwml1), Sphingopyxis sp. Kp5.2 (1.0 mgcdw
ml1), Rhodococcus opacus 1CP (0.98 mgcdwml1), and Gordonia sp. CWB2
(1.9 mgcdwml1) were incubated for 12 h in the presence of 25 mmol 3-
chlorostyrene. 3-Chlorophenylacetic acid formation was followed and referred to
cell dry weight. Mean values and standard errors of three to four independent
measurements are given.
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phenylacetic acids
Glucose-grown and styrene-induced cell suspensions of
P. ﬂuorescens ST, Sphingopyxis sp. Kp5.2, R. opacus 1CP, and Gordonia
sp. CWB2 (Supplemental materials Fig. S1, a–d) were treated as
described in Section 2, in the course of this adjusted to an OD600 of
about 1–6 (corresponding to 0.61–1.9 mgcelldryweight ml1), and
subsequently incubated in the presence of volatilized substituted
styrenes. Analogs were either halogenated (3-chloro, 4-chloro-,
4-ﬂuorostyrene), alkylated (a-methyl-, 4-isobutyl-a-methylstyr-
ene), or both (4-chloro-a-methylstyrene) (see Fig. 1). During the
course of 12 h the formation of corresponding phenylacetic acids
was followed and product amounts obtained were referred to the
biomass content. All four strains were found to convert most of the
styrenes (Figs. 3 and 4). However, speciﬁc conversion yields
differed considerably ranging from 28 to 520 mmol gcdw1 after
12 h for 4-chlorostyrene which was chosen as a reference
compound in order to normalize conversion yields. P. ﬂuorescens
ST turned out to be the by far most active isolate for that substrate
(520  21 mmol gcdw1 during 12 h) followed by strain Kp5.2
(98.2  6.9 mmol gcdw1), strain CWB2 (67.7  8.8 mmol gcdw1),
and strain 1CP (27.9  2.0 mmol gcdw1).
Signiﬁcant differences were also observed for the substrate
tolerance of isolates of which strain Kp5.2 probably showed the
highest one (Fig. 3). 3-Chloro-, 4-chloro-, and 4-ﬂuorophenylacetic
acid were formed with relative yields of (nearly) 100% after 12 h
and a-methylphenylacetic acid was accumulated even faster with
151% compared to the reference 4-chlorophenylacetic acid.
However, the absolute transformation rates were considerably
lower than in the case of strain ST.
In general, strains exhibited low activities towards 4-chloro-
a-methylstyrene. The corresponding acid was formed by strain ST
in a relative yield of about 33%. With an additional isobutyl-group
in para-position of the phenyl moiety, the substrate tolerance ofFig. 3. Substrate speciﬁcities of strains ST, Kp5.2, 1CP, and CWB2 for the conversion
of substituted styrenes into the corresponding phenylacetic acids.
Pseudomonas ﬂuorescens ST (0.61 mgcdwml1), Sphingopyxis sp. Kp5.2 (1.0 mgcdw
ml1), Rhodococcus opacus 1CP (0.98 mgcdwml1), and Gordonia sp. CWB2
(1.9 mgcdwml1) were cultivated for 12 h in the presence of 25 mmol substrate as
described in the Section 2. If not otherwise stated, the substrate was provided via
gas phase. The product yields obtained during a period of 12 h were referred to the
cell dry weight and normalized towards 4-chlorophenylacetic acid formation
(=100%). Mean values and standard errors of three to four independent
measurements are given. 100% rel. yields correspond to: strain ST: 520  21 mmol
gcdw1; strain Kp5.2: 98.2  6.9 mmol gcdw1; strain CWB2: 67.7  8.8 mmol gcdw1;
strain 1CP: 27.9  2.0 mmol gcdw1.most isolates was exhausted. The corresponding 4-isobutyl-
a-methylphenylacetic acid (ibuprofen) was only detected from
conversions of strain CWB2, a fact that might emphasize this
isolate for the production of this drug. Although ibuprofen
was detected with only 3.45  0.48 mmol gcdw1 after 12 h from
CWB2-catalyzed biotransformation, minor yields are to some
extent caused by the low bioavailability of 4-isobutyl-a-methyl-
styrene. The direct addition of the pure compound into the
medium increased the product formation by the factor ﬁve to
17.4  0.9 mmol gcdw1 after 12 h (Fig. 3). The remarkable ability of
strain CWB2 to produce ibuprofen indicates substantial differences
of at least one of the enzymes involved in the biotransformation.
Whereas for strain Kp5.2, 1CP, and ST the styrene-catabolic
genes for initial styrene degradation have been identiﬁed and
corresponding SOI activity has been determined during previous
studies [5,7,35], attempts to detect the styC-encoded styrene
oxide isomerase in strain CWB2 failed because no SOI activity was
found [35].
The results obtained suggest that the enzymes of the upper
styrene degradation are able to catalyze the transformation of
substituted styrenes to the corresponding phenylacetic acids.
Moreover, substitution obviously impairs ability of phenylacetyl-
CoA ligase or ring 1,2-phenylacetyl-CoA epoxidase (as described by
[46] to metabolize these artiﬁcial structure analogs. This leads to
an accumulation of these phenylacetic acids in the culture
medium. Since the speciﬁc conversion yields of strain ST surpassed
the yields of the other ones (e.g. demonstrated by Fig. 4) and since
strain CWB2 was able to produce ibuprofen (Fig. 3), both isolates
are of special interest.
3.3. Stereoselective conversion of 4-chloro-a-methylstyrene
As illustrated in Fig. 1 the conversion of an a-substituted
styrene to the corresponding phenylacetic acid results in the
creation of an asymmetric center at C-2. Chiral HPLC was
performed in order to investigate the potential of the four strains
for enantioselective production of 4-chloro-a-methylphenylacetic
acid and to determine the overall behavior of initial enzymes. An
appreciable enantioselectivity was obtained for P. ﬂuorescens ST
which yielded about 43% ee of the (S)-enantiomer. Enantioprefer-
ence of strain 1CP (20% ee of (S)-isomer) and strain CWB2 (15% ee
of (R)-isomer) was considerably lower and almost absent for strain
Kp5.2.
The two initial enzymes of side-chain oxygenation have been
shown to be responsible for the formation of an asymmetric center
Fig. 6. Utilization of strain CWB2 for the formation of 4-isobutyl-a-methylphe-
nylacetic acid (ibuprofen).
A cell suspension of Gordonia sp. CWB2 (1.9 mgcdwml1) was incubated for 28 days
in the presence of in total 650 mmol 4-isobutyl-a-methylstyrene (50–100-mmol
portions) as described in the Section 2. Product formation was determined by HPLC
(see Section 2). Mean values and standard errors of two to three independent
measurements are given.
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monooxygenases (SMOs) introduce the oxygen atom highly
enantioselective and most representatives investigated in that
respect strongly favor the formation of the (S)-enantiomer of
styrene oxide [31]. At second, the few styrene oxide isomerases
characterized clearly prefer the conversion of this (S)-enantiomer
of styrene oxide into phenylacetaldehyde [30,22,35]. In the case of
an a-substitution SOI would again affect the absolute conﬁgura-
tion of the product. The ﬁnal enzyme phenylacetaldehyde
dehydrogenase of the metabolic cascade proposed does not act
on the chiral carbon and thus should not affect stereochemistry.
Highly enantioselective biotechnological synthesis of a-meth-
ylphenylacetic acid has been reported by Gilligan et al. [16]
using (R,S)-2-phenylpropionic nitrile. However, biotechnological
enantioselective production of a-substituted phenylacetic acids
from corresponding styrenes has not been described before
and indicates that some SOIs effectively affect the absolute
conﬁguration of the product.
3.4. Microbial production of substituted phenylacetic acids
The co-metabolic formation of 4-chloro-a-methyl- and
4-chlorophenylacetic acid by P. ﬂuorescens ST and of 4-isobutyl-
a-methylphenylacetic acid (ibuprofen) by Gordonia sp. CWB2 was
extended to longer periods of time in order to evaluate process
stability and to maximize yield. Additionally supplemented
styrene served as an energy source for the supply of reduction
equivalents and as an inducer for relevant enzyme activities.
Glucose-grown and styrene-induced biomass of strain ST was
adjusted to an OD600 of about 0.8 which corresponds to a biomass
titer of 0.41 mgcdwml1. During the course of 348 days, 3630 mmol
4-chlorostyrene and 1750 mmol styrene were in parallel spiked
through the gas phase. Conversion of 4-chlorostyrene was shown
to be nearly quantitative (96% theory yield) over a period of
214 days (Fig. 5a), but decreased in efﬁciency for the following 134
days (87% theory yield). About 3150  90 mmol (=537  15 mg)
4-chlorophenylacetic acid were obtained referred to the initial
biomass amount of 82 mgcdw. Phenylacetic acid, which might occur
as a metabolite from the natural substrate styrene, was not
detected at signiﬁcant levels and thus did not affect product
recovery and purity.
Another aliquot of the cell suspension of strain ST mentioned
before was applied in the transformation of 374 mmol 4-chloro-
a-methylstyrene. Again, styrene was supplemented inFig. 5. Applicability of strain ST for the formation of 4-chloro- and 4-chloro-a-methyl
Pseudomonas ﬂuorescens ST (0.41 mgcdwml1) was incubated for 348 days in the presenc
25 days with overall 374 mmol 4-chloro-a-methylstyrene (added in 20–41-mmol porti
Section 2). Mean values and standard errors of four independent measurements are giapproximately half of this molar amount. A linear correlation
between substrate addition and product formation was restricted
here for 8 days and conversion completely stagnated after
11–14 days to yield 81.4 1.9 mmol (=15.0  0.4 mg) 4-chloro-
a-methylphenylacetic acid (Fig. 5b). Compared to the conversion
of 4-chlorostyrene, process stability and transformation efﬁciency
is considerably limited.
A similar effect was observed during the conversion of the
sterically most demanding substrate 4-isobutyl-a-methylstyrene.
In the presence of 600 mmol of this compound and in the course
of 23 days, the biomass of Gordonia sp. CWB2 (OD600 of about
6.0; 1.9 mgcdwml1) accumulated up to 65.2  2.1 mmol
(=13,4  0.4 mg) ibuprofen (Fig. 6). Again, the kinetics obtained
clearly pointed at an inactivation event. A second experiment with
a more limited substrate supply yielded similar results (data not
shown) which excludes reversible substrate inhibition to be the
reason for process stagnation.
Several studies have reported on an antimicrobial activity of
this anti-inﬂammatory compound especially towards gram-phenylacetic acid.
e of in total 3630 mmol 4-chlorostyrene (added in 21–42-mmol portions) (a) or for
ons) (b) as described in Section 2. Product formation was quantiﬁed by HPLC (see
ven.
M. Oelschlägel et al. / Biotechnology Reports 6 (2015) 20–26 25positive bacteria. Depending on the pH, growth suppression was
observed at levels below 150 mg ml1 [13] which are in the range of
this biotransformation approach. According a more recent study,
minimal inhibition concentration towards the Gram-positive
isolate Staphylococcus aureus has been reported to be one order
of magnitude higher (minimal inhibition concentration = 1.25 mg
ml1) [1]. However, the strains investigated showed different
susceptibilities and it has still to be examined, to what extent strain
CWB2 is susceptible towards this drug.
4. Conclusion
In summary, the study has revealed that substituted phenyl-
acetic acids can in principal be produced from correspondingly
substituted styrenes by means of suitable styrene-degrading
bacterial isolates which harbor enzymes of the side-chain
oxygenation. 4-chlorostyrene turned out to be a well suited
co-metabolic substrate and in particular, it was most efﬁciently
converted by P. ﬂuorescens ST. Considerable differences were also
observed in the enantioselective potential of the initial degrada-
tion pathway relevant in the conversion of a-substituted styrene
analogs. Again, strain ST showed highest speciﬁcity and an
enantiomeric excess of 40% was determined for the (S)-4-
chloro-a-methylphenylacetic acid. The remarkable ability of a
Gordonia-isolate to convert 4-isobutyl-a-methylstyrene into
ibuprofen demonstrates a novel route towards this drug. However,
a biotechnological application of these strains requires further
optimization approaches to improve the product yields.
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